Heartflow (NASDAQ:HTFL) Upgraded to “Strong-Buy” at Robert W. Baird

Robert W. Baird upgraded shares of Heartflow (NASDAQ:HTFL) to a strong-buy rating in a research report report published on Friday,Zacks.com reports.

HTFL has been the topic of several other research reports. Weiss Ratings lowered shares of Heartflow from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, July 8th. Piper Sandler reissued an “overweight” rating on shares of Heartflow in a report on Thursday, June 11th. Stifel Nicolaus set a $40.00 target price on Heartflow in a research report on Wednesday, July 15th. Freedom Capital raised Heartflow to a “strong-buy” rating in a research note on Tuesday, June 30th. Finally, Wells Fargo & Company boosted their price target on Heartflow from $35.00 to $37.00 and gave the stock an “overweight” rating in a research report on Friday, May 15th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $36.57.

Heartflow Stock Performance

Shares of HTFL opened at $25.23 on Friday. The firm has a fifty day moving average of $29.02 and a 200-day moving average of $28.10. The company has a market cap of $2.18 billion and a price-to-earnings ratio of -8.11. Heartflow has a 1 year low of $20.13 and a 1 year high of $41.22.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.08. The firm had revenue of $52.59 million during the quarter. The business’s revenue was up 41.3% on a year-over-year basis. Analysts predict that Heartflow will post -0.82 EPS for the current year.

Insider Buying and Selling

In other news, CEO John C.M. Farquhar sold 22,562 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $27.75, for a total value of $626,095.50. Following the completion of the sale, the chief executive officer directly owned 435,373 shares of the company’s stock, valued at approximately $12,081,600.75. This represents a 4.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 9,219 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $28.34, for a total transaction of $261,266.46. Following the completion of the transaction, the insider owned 78,731 shares of the company’s stock, valued at $2,231,236.54. This trade represents a 10.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 115,805 shares of company stock valued at $3,548,884. Company insiders own 7.70% of the company’s stock.

Institutional Trading of Heartflow

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. acquired a new stake in shares of Heartflow in the third quarter valued at $48,871,000. Legal & General Group Plc acquired a new position in Heartflow during the third quarter worth about $59,000. Franklin Resources Inc. bought a new stake in Heartflow in the third quarter worth about $10,829,000. UBS Group AG bought a new stake in Heartflow in the third quarter worth about $5,130,000. Finally, Sei Investments Co. acquired a new stake in Heartflow in the 3rd quarter valued at about $303,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.